EE370 Assessing the Impact of Crossover Adjustment on the Cost-Effectiveness (CE) of Nivolumab Versus Everolimus in Pre-Treated Advanced Renal Cell Carcinoma (ARCC) in the United States (US)
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.618
https://www.valueinhealthjournal.com/article/S1098-3015(22)00819-1/fulltext
Title :
EE370 Assessing the Impact of Crossover Adjustment on the Cost-Effectiveness (CE) of Nivolumab Versus Everolimus in Pre-Treated Advanced Renal Cell Carcinoma (ARCC) in the United States (US)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00819-1&doi=10.1016/j.jval.2022.04.618
First page :
Section Title :
Open access? :
No
Section Order :
10551